What is the recommended initial treatment and adjuvant therapy for a patient with seminoma staged T2N0M0 (tumor >5 cm, no nodal involvement, no distant metastasis)?

Treatment of Seminoma T2N0M0 (Stage IB)

For a patient with seminoma T2N0M0 (tumor >5 cm, no nodal involvement), surveillance is the strongly preferred initial management strategy after radical inguinal orchiectomy, with adjuvant carboplatin as an alternative for patients unwilling or unable to comply with surveillance protocols. 1

Initial Treatment: Radical Inguinal Orchiectomy

• Radical inguinal orchiectomy is both diagnostic and therapeutic, and must be performed before any adjuvant therapy 1
• Sperm cryopreservation should be offered before any treatment 1
• Tumor markers (AFP, β-HCG, LDH) must be assessed before and after orchiectomy until normalization to confirm pure seminoma and guide staging 1

Post-Orchiectomy Management Options

Surveillance (Preferred Strategy)

Surveillance is the preferred option for stage IB seminoma despite the tumor size >5 cm, as disease-specific survival approaches 99-100% regardless of management strategy. 1

• The relapse rate for stage I seminoma with risk factors (tumor >4 cm) is approximately 15-32% 1, 2
• Most relapses occur in retroperitoneal lymph nodes within the first 2 years 1
• Surveillance should be undertaken for at least 5 years with regular abdominal imaging 1

Surveillance Protocol:

• Clinical examination and tumor markers: every 3-4 months for years 1-2, every 6-12 months for years 3-4, then annually thereafter 1
• Abdominal/pelvic CT: every 6 months for years 1-2, every 6-12 months for year 3, then annually for years 4-5 1
• Chest radiographs may be performed at similar intervals 1

Adjuvant Carboplatin (Alternative for High-Risk or Non-Compliant Patients)

If surveillance is not applicable due to patient preference, inability to comply with follow-up, or high-risk features, one cycle of carboplatin AUC 7 should be offered. 1

• Carboplatin dose calculation: 7 × (GFR [mL/min] + 25 mg) 1
• One cycle of carboplatin reduces relapse rate to approximately 5-9% in high-risk patients 1, 2
• Two cycles of carboplatin further reduce relapse to 1.5%, but the panel does not currently recommend single-cycle carboplatin due to limited long-term data 1
• Relapse-free survival at 5 years with one cycle carboplatin is 94.7-95% 1

Adjuvant Radiotherapy (Generally Not Recommended)

Adjuvant radiotherapy should NOT be offered as first-line adjuvant therapy due to the significant long-term risk of second malignancies and cardiovascular disease. 1

• If radiotherapy is used (only when carboplatin and surveillance are not options), deliver 20 Gy in 10 fractions over 2 weeks to para-aortic strip (T10-L5) 1
• Radiotherapy carries a 28-80% increased risk of death from secondary malignancies and non-cancer causes 1
• The risk of second malignancy is considered too high relative to the excellent prognosis 1

Key Clinical Considerations

Risk Stratification

• Tumor size >4 cm is a validated risk factor for relapse (15-32% relapse rate vs. 12% for tumors <4 cm) 1, 2
• Rete testis invasion is the other major risk factor 1, 2
• However, some validation studies question these risk factors, and risk-adapted management based solely on tumor size is discouraged by some guidelines 1

Treatment Selection Algorithm

1. First choice: Surveillance for all compliant patients with access to regular imaging 1
2. Second choice: One cycle carboplatin AUC 7 for patients unwilling/unable to undergo surveillance or with high-risk features 1
3. Avoid: Adjuvant radiotherapy due to long-term toxicity concerns 1

Common Pitfalls

• Do not treat based on elevated LDH alone - this is not sufficient for treatment escalation 1
• Do not use two cycles of carboplatin routinely - insufficient long-term data despite lower relapse rates 1
• Avoid scrotal violation during any diagnostic or surgical procedures 1
• Do not offer carboplatin to low-risk patients (tumor <4 cm without rete testis invasion) 1

Management of Relapse

• Patients on surveillance who relapse can be treated with radiotherapy or chemotherapy depending on extent of disease 1
• Patients who received carboplatin or radiotherapy and relapse should be treated with first-line cisplatin-based chemotherapy (BEP or EP regimens) 1
• Salvage treatment achieves excellent outcomes with disease-specific survival remaining near 100% 1